Filtered By:
Drug: Avapro

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research

A review of the use of Angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
CONCLUSIONS: Data supporting the use of ARBs for reducing cardiovascular events in patients with essential hypertension without compelling indications are limited and inconclusive. More studies are needed before ARBs can be routinely recommended as first-line therapy for hypertension management in patients without other compelling indications. PMID: 23585649 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: Zaiken K, Hudd TR, Cheng JW Tags: Ann Pharmacother Source Type: research

Telmisartan, valsartan lower risk of CVD complications in diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations.
Source: theHeart.org - July 8, 2013 Category: Cardiology Source Type: news

Two ARBs Lower Risk of CVD Complications in DiabeticsTwo ARBs Lower Risk of CVD Complications in Diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations. Heartwire
Source: Medscape Today Headlines - July 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetics Taking Certain Blood Pressure Drugs At Lower Risk Of Heart Disease
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal). For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure...
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news

Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial
Conclusions In diabetic individuals with nephropathy, systolic blood pressure visit-to-visit variability is associated independently with hard kidney disease outcomes.
Source: American Journal of Kidney Diseases - October 29, 2014 Category: Urology & Nephrology Source Type: research

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)
Conclusions In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations.
Source: American Journal of Kidney Diseases - August 21, 2015 Category: Urology & Nephrology Source Type: research

Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy
Conclusions The combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy varies considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: Nicolette G.C. van der Sande, Jannick A.N. Dorresteijn, Frank. L.J. Visseren, Jamie P. Dwyer, Peter J. Blankestijn, Yolanda van der Graaf, Hiddo L. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy
ConclusionsThe combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy vary considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - August 11, 2016 Category: Endocrinology Authors: N. G. C. Sande, J. A. N. Dorresteijn, F. L. J. Visseren, J. P. Dwyer, P. J. Blankestijn, Y. Graaf, H. L. J. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Predictors of Mortality in Patients with Atrial Fibrillation (From the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ACTIVE a)
The mortality rate of most patients with atrial fibrillation (AF) exceeds the stroke rate, but predictors of mortality have not been well defined. The Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE) recruited AF patients who were unsuitable to receive vitamin K-antagonists and were randomized to aspirin alone vs. aspirin plus clopidogrel. We investigated independent predictors of all-cause mortality by multivariable Cox regression analysis and explored interactions with assigned antiplatelet therapy.
Source: The American Journal of Cardiology - December 11, 2017 Category: Cardiology Authors: Kanjana S. Perera, Lesly A. Pearce, Mukul Sharma, Oscar Benavente, Stuart J. Connolly, Robert G. Hart, ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators Source Type: research

Covariate adjusted reanalysis of the I-Preserve trial
ConclusionAdjusting for imbalances in baseline variables that influence outcomes (or the response to therapy or both) can improve the power around the estimate of the effect of treatment and may alter its statistical significance. Along with the CHARM-Preserved results, these findings suggest that angiotensin-receptor blockers may have a modest effect in HFpEF.
Source: Clinical Research in Cardiology - March 24, 2020 Category: Cardiology Source Type: research

Irbesartan suppresses lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) dysfunction by inhibiting the activation of MLCK/MLC
Int Immunopharmacol. 2021 Jun 23;98:107834. doi: 10.1016/j.intimp.2021.107834. Online ahead of print.ABSTRACTThe basic function of the blood-brain barrier (BBB) is to selectively regulate the infiltration of solutes from the circulating blood into the central nervous system (CNS). Impaired BBB activity is related to brain damage caused by stroke, traumatic injury, neurodegenerative diseases, etc. Comprised of a monolayer of endothelial cells, the integrity of the BBB is determined by the expression of tight junction proteins and the contractile activity of the perijunctional apical actomyosin ring. Irbesartan, an AT1R anta...
Source: International Immunopharmacology - June 26, 2021 Category: Allergy & Immunology Authors: Qixia Yang Juanjuan Yu Hao Qin Long Liu Chao Di Qiang Zhuang Hang Yin Source Type: research